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Urinary excretion of angiotensinogen reflects intrarenal angio- rial pressure and sodium homeostasis through the action
tensinogen production. of renin on angiotensinogen to form various angiotensin
Background. In rats maintained on a high salt diet (H/S) (Ang) peptides and subsequent activation of Ang recep-to suppress basal renal angiotensinogen levels, angiotensin II
tors [1]. Angiotensinogen is the only known substrate(Ang II) infusion for 13 days increased renal angiotensinogen
for renin and the level of angiotensinogen in humans andmRNA and protein, thus providing a mechanism for further
augmentation of intrarenal Ang II levels. The present study rats is close to the KM value for renin [2]. Thus, changes
tested the hypothesis that enhanced intrarenal angiotensinogen in angiotensinogen levels can control the activity of the
formation during Ang II infusion is reflected by secretion into RAS, and its up-regulation may lead to elevated Angthe tubular fluid leading to increased urinary excretion of an-
levels and increases in BP. Recent evidence based ongiotensinogen (UAGT).
experimental animal models and transgenic mice whichMethods. The effects of chronic Ang II infusion were exam-
ined on kidney and plasma Ang II levels and UAGT in male have an increased activity of the RAS have documented
Sprague-Dawley rats maintained on an 8% salt diet for three the involvement of angiotensinogen in the development
weeks (N  10). Following one week on the H/S diet, Ang II
of hypertension [3–5]. In human genetic studies, a link-(40 ng/min) was administered for two weeks via an osmotic
age has been established between the angiotensinogenminipump to one group (H/S  Ang II, N  5), while the
remaining rats were sham-operated (H/S  Sham, N  5). gene and hypertension [6]. Genetic manipulations that
Additionally, a control group was prepared with normal salt lead to overexpression of angiotensinogen have consis-
diet and sham-operation (N/S  Sham, N  5). tently been shown to cause hypertension further demon-
Results. H/S alone did not alter systolic blood pressure (BP)
strating an important role of angiotensinogen in BP regu-(103  2 vs. 104  2 mm Hg), while Ang II infusion to H/S
lation [3].rats significantly increased systolic BP from 103  2 to 154 
2 after two weeks. Intrarenal Ang II content in H/S  Ang II While several Ang peptides are produced by the RAS
was significantly greater than H/S Sham (435 153 vs. 65  cascade, Ang II is the most extensively characterized pep-
14 fmol/g). Ang II infusion significantly increased UAGT (4.0  tide produced from its prohormone angiotensinogen.0.5 vs. 1.0  0.2 nmol Ang I/day by radioimmunoassay of
Considerable evidence supports the involvement of inap-generated Ang I; 57  15 vs. 14  2 densitometric units by
propriately elevated intrarenal Ang II levels in manyWestern blotting analysis) compared to Sham. UAGT by radioim-
munoassay was highly correlated with kidney Ang II content forms of hypertension [7, 8]. Chronic infusion of Ang II
(r  0.79); but not with plasma Ang II concentration (r  provides a useful experimental model of Ang II-depen-
0.20). dent hypertension that resembles the 2-kidney–1-clipConclusions. These data demonstrate that chronic Ang II in-
Goldblatt hypertension model and is characterized byfusion increases urinary excretion rate of angiotensinogen, and
progressive increases in intrarenal Ang II to levelssuggest that UAGT provides a specific index of intrarenal angio-
tensinogen production in Ang II-dependent hypertension. greater than can be explained by the modest increases
in circulating Ang II concentrations [7, 9, 10]. The mecha-
nisms responsible for the ability of moderate increases
It is well recognized that the renin-angiotensin system in circulating Ang II to cause progressive increases in
(RAS) plays an important role in the regulation of arte- intrarenal Ang II involve increased receptor-mediated
Ang II internalization and increased intrarenal Ang II
production [7, 9–12]. Previous studies have demonstratedKey words: Ang II, kidney, urine, high salt diet, hypertension, renin-
angiotensin system, blood pressure. that Ang II infusion results in significant increases in
renal expression of angiotensinogen mRNA [11, 12] andReceived for publication May 11, 2001
protein [13]. In particular, Ang II infusion elicited in-and in revised form August 13, 2001
Accepted for publication September 17, 2001 creases in both mRNA and protein in rats maintained
on a high salt (H/S) diet [13]. This amplification of angio- 2002 by the International Society of Nephrology
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tensinogen substrate by Ang II itself may be one mecha- [16, 25]. Urine samples were centrifuged and supernatant
was separated and stored at20C until assayed for cre-nism by which Ang II produces its progressive hyperten-
sinogenic effects. atinine and angiotensinogen concentrations. Blood and
kidney samples were harvested on day 14. After decapi-Because intrarenal angiotensinogen is localized pri-
marily to proximal tubular cells [12] and has been found tation, trunk blood was collected into chilled tubes con-
taining EDTA (5 mmol/L), enalaprilat (20mol/L), pep-in proximal tubular fluid [14], we hypothesized that a
portion of the enhanced renal angiotensinogen would statin A (10 mol/L), and 1,10-phenanthroline (1.25
mmol/L). Plasma was separated and stored at 20Cbe secreted into the tubular fluid and ultimately excreted
in the urine in Ang II-induced hypertension. Angioten- until assayed for plasma renin activity and Ang II con-
centration as previously described [12, 13]. Immediatelysinogen has been shown to be present in urine [15];
however, only few reports have assessed the origin, func- after removal, kidneys were homogenized in cold metha-
nol and processed for measurement of renal Ang II astion, or regulation of urinary angiotensinogen, as well as
the pathophysiological role of urinary angiotensinogen previously described [12, 13].
[16–19]. The present study explored the changes in uri-
Measurements of urine samplesnary excretion of angiotensinogen that occur in Ang II-
induced hypertension and the relationships with intra- Urinary concentrations of creatinine were measured
by a standard Jaffe reaction. Urine excretion of angioten-renal and plasma Ang II levels. The results support the
hypothesis that urinary excretion of angiotensinogen sinogen was evaluated by a radioimmunoassay (RIA)
[9, 13] and Western blotting analysis [12].provides an index of intrarenal, and more specifically
tubular Ang activity. The RIA was performed to measure Ang I generation
with excess amount of exogenous porcine renin (R 2761;
Sigma, St. Louis, MO, USA). RIA of Ang I was performed
METHODS
with a commercially available kit (Incstar, Stillwater, MI,
Preparation of animals and samples USA) using the directions and reagents supplied by the
manufacturer. Urine samples were incubated with reninThe experimental protocol was approved by the Tu-
lane University Animal Care and Use Committee. Male at 37C and removed from incubation at 0, 10, 30, 60,
and 120 minutes. Samples were appropriately dilutedSprague-Dawley rats (Charles River, Wilmington, MA,
USA) were housed in wire metabolic cages and main- with reagent blank so that the RIA results were on the
linear portion of the standard curve. The amount of Angtained in a temperature-controlled room regulated on a
12-hour light/dark cycle with free access to water. Since I generated at each time point was then obtained by
comparison to the standard curve. The Ang I producedthe H/S diet has been shown to suppress basal angioten-
sinogen expression [20–22], rats (N  15) were main- was then plotted versus time and saturation kinetics due
to conversion of all angiotensinogen to Ang I was ob-tained on commercially available rat chow containing
H/S (8% sodium chloride; Harlan Teklad, TD 79119, served by 60 minutes.
Western blotting analysis was performed with a stan-Madison, WI, N 10) or normal salt (N/S, 0.6% sodium
chloride, Harlan Teklad, #170950, N 5) for three weeks dard protocol [12, 13]. The same fraction (1.2  104) of
the 24-hour urinary volume (equivalent to the calculated(1 week prior and 2 weeks during Ang II infusion). Rats
(180 2 g) were anesthetized with sodium pentobarbital urine volume of 10 sec) for each animal was separated
by electrophoresis using pre-cast NuPAGE 4 to 12% Bis-(50 mg/kg, IP), and an osmotic minipump (Alza, Palo
Alto, CA) was implanted subcutaneously at the dorsum Tris gel (Invitrogen, Carlsbad, CA, USA). The proteins
from the gel were electrophoretically transferred to a ni-of the neck on day 0. Rats were selected at random
from the H/S group to receive Ang II infusion (N  5, trocellulose membrane (Bio-Rad, Hercules, CA, USA)
using the XCell II Mini-Cell (Invitrogen). The mem-Calbiochem-Novabiochem, La Jolla, CA, USA) at a rate
of 40 ng/min for a period of two weeks or were subjected brane was incubated with the primary antibody [26]
(sheep anti-rat angiotensinogen, 1:5000) for three hours,to a sham-operation (N  10). As previously shown [13,
23, 24], rats maintained on a H/S diet develop equivalent washed, incubated with the secondary antibody conju-
gated to horseradish peroxidase (donkey anti-sheep IgG,hypertension at lower Ang II infusion rates.
Systolic blood pressure was measured in conscious rats 1:30000; Sigma) for one hour, and washed. Detection
was accomplished using enhanced chemiluminescenceusing a computerized tail-cuff plethysmography (Visi-
tech, BP-2000, Apex, NC, USA) on days 6, 0, 6 and ECL kit (Amersham Pharmacia Biotech, Piscataway, NJ,
USA), and the blots were exposed to x-ray film (Hyper-12 of the Ang II infusion period. Twenty-four–hour urine
samples were collected on days 7 and 13 in 0.6 mL film-ECL; Amersham Pharmacia Biotech). Autoradio-
graph films were scanned using Digital Imaging anddistilled water containing 50 g pepstatin, 10 mg sodium
azide, 300 nmol enalaprilat, and 125 mol ethylenedi- Analysis Systems (Alpha Innotech, San Leandro, CA,
USA) to obtain integrated densitometric unit (du).aminetetraacetic acid (EDTA) as previously reported
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Table 1. Systolic blood pressure (SBP) profile and parameters after treatment in each group
Parameters Units N/SSham H/SSham H/SAng II
SBP mm Hg
at day 6 1042 1052 1042
at day 0 1042 1032 1032
at day 6 1022 1053 1164abc
at day 12 1052 1042 1542abc
Plasma renin activity ng Ang I/mL/h 4.00.9 1.20.4a 0.20.1a
Plasma Ang II fmol/mL 6332 6027 9148
Kidney Ang II fmol/g 10332 6514 435153ab
Urine volume mL/day 151 6310a 10111ab
UCr lg/day 85830 896131 855179
UAGT-R/UCr lmol/g 1.50.4 1.10.3 4.81.0ab
UAGT-W/UCr du/mg/day 91 184 8813
Data are mean  SEM values. Abbreviations are: N/S, normal salt diet; H/S, high salt diet; Ang, angiotensin; UCr, urinary excretion of creatinine; UAGT, urinary excre-
tion of angiotensinogen; -R, measured by a radioimmunoassay; -W, evaluated by Western blotting analysis; du, integrated densitometric unit. N  5 in each group.
a P  0.05 vs. N/S  Sham
b P  0.05 vs. H/S  Sham
c P  0.05 vs. day 0
As a control study, membranes were re-probed with sham-operated rats maintained on the H/S diet, but the
changes were not statistically significant (Table 1). How-an antibody against major urinary protein that is a phero-
mone transport protein, which would not be expected ever, kidney Ang II content was significantly increased
by sevenfold in the Ang II-infused rats maintained onto be regulated by Ang II [27]. After first detection,
membranes were incubated with Western Re-Probe so- the H/S diet compared with sham-operated rats main-
tained on the H/S diet (Table 1). These results are consis-lution (Geno Technology, St. Louis, MO, USA) for one
hour according to the manufacturer’s protocol. Then, tent with our previous results obtained in rats subjected
to an identical protocol demonstrating significant in-membranes were incubated with the primary antibody
(goat anti-mouse major urinary protein, 1:1000; Accurate creases in kidney angiotensinogen mRNA and angioten-
sinogen protein [13].Chemical and Scientific Corporation, Westbury, NY,
USA) for two hours, washed, incubated with the second-
Urinary excretion of angiotensinogenary antibody conjugated to horseradish peroxidase (bo-
vine anti-goat IgG, 1:5000; Santa Cruz Biotechnology, Twenty-four–hour urinary volumes were similar among
the three groups at the beginning of the protocol (11 Santa Cruz, CA, USA) for one hour, and washed. Detec-
tion and evaluation were done as described above. 1 for N/S  Sham, 12  2 for H/S  Sham, and 13  1
mL/day for H/S  Ang II at day 7). The H/S diet
Statistical analysis induced significant increases in urine volume in the
H/S  Sham compared to the N/S  Sham group andStatistical analysis was performed using a one-way
ANOVA with the post hoc Scheffe F test. All data are further increases in the H/S  Ang II group (Table 1).
Urinary creatinine was used as a test of completenesspresented as mean  SEM. P  0.05 was considered
significant. of urine collections. Urinary excretion rates for creati-
nine were similar among the three groups at the begin-
ning of the protocol (779  142 for N/S  Sham, 653 
RESULTS
188 for H/S  Sham, and 726  125 g/day for H/S 
Blood pressure, plasma renin activity, and plasma and Ang II). As shown in the Table 1, daily urinary excretion
renal Ang II content rates of creatinine were also similar among the three
groups after three weeks of treatment.Systolic blood pressure (SBP; Table 1) was similar
among the three groups before implantation of the os- Urinary excretion rates of angiotensinogen evaluated
by RIA of Ang I production were not different at themotic minipumps. The H/S diet alone did not alter SBP
as compared to N/S rats. Ang II infusion to rats main- onset of the protocol (1.4  0.1 for N/S  Sham, 1.4 
0.2 for H/S  Sham, and 1.6  0.1 nmol/day for H/S tained on a H/S diet caused a significant increase in SBP
from 103  2 to 116  4 and 154  2 mm Hg at 0, 6 Ang II at day 7). Ang II infusion to rats on H/S diet
significantly increased urinary angiotensinogen excretionand 12 days, respectively.
The H/S diet markedly suppressed plasma renin activ- compared with N/S  Sham and H/S  Sham groups
(Fig. 1A). The urinary angiotensinogen excretion ratesity (Table 1) compared with N/S  Sham rats.
Plasma Ang II concentration was 50% higher in Ang II- remained at control levels in both sham groups but in-
creased by fourfold in the Ang II-infused rats. Also, theinfused rats maintained on the H/S diet compared with
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ratio of urinary excretion of angiotensinogen evaluated
by RIA to urinary excretion of creatinine showed a simi-
lar pattern. The ratio was similar before the treatment
(2.0  0.4 mol/g for N/S  Sham, 2.7  0.6 for H/S 
Sham, 2.8  1.1 for H/S  Ang II); however, Ang II
infusion to rats on H/S diet significantly increased the
ratio compared with N/S  Sham and H/S  Sham
groups (Table 1).
Urinary angiotensinogen levels evaluated by Western
blotting analysis were similar before treatment (24  7
du for N/S  Sham, 30  9 du for H/S  Sham, and
26  8 du for H/S  Ang II; Fig. 1C). Ang II infusion
to rats on the H/S diet significantly increased urinary
angiotensinogen levels by fourfold compared with H/S
Sham group (Fig. 1 B, E). The ratios of urinary angioten-
sinogen levels evaluated by Western blotting analysis to
urinary excretion of creatinine showed a similar pattern
and was not different before the treatment (33  8 for
N/S  Sham, 55  16 for H/S  Sham, and 39  10 du/
mg/day for H/S  Ang II); however, Ang II infusion to
rats on H/S diet significantly increased the ratio ap-
proximately fivefold compared with H/S  Sham group
(Table 1).
Urinary excretion of major urinary protein evaluated
by Western blotting analysis was not different prior to
treatment (19  2 du for N/S  Sham, 18  1 du for
H/S  Sham, and 23  6 du for H/S  Ang II; Fig. 1D).
Ang II infusion to rats on the H/S diet did not change
the urinary excretion of major urinary protein compared
with the H/S  Sham or N/S  Sham group (23  3 du
for N/S  Sham, 25  4 du for H/S  Sham, and 26 
3 du for H/S  Ang II; Fig. 1F). These results indicate
that enhancement of urinary excretion of angiotensino-
gen by Ang II was not the result of non-specific increases
in protein excretion, but was rather the result of a specific
stimulation of angiotensinogen production.
Correlation of Ang II levels and urinary
angiotensinogen after treatment
Urine excretion rates of angiotensinogen after the
treatment evaluated by RIA of Ang I were plotted
against kidney (Fig. 2A) and plasma (Fig. 2B) Ang II
levels. Urine angiotensinogen excretion rates showed a
high correlation with kidney Ang II content (r  0.79);Fig. 1. Urinary angiotensin levels evaluated by a radioimmunoassay
however they were not correlate with plasma Ang II(RIA) of generated angiotensin I (Ang I; A) and Western blotting
analysis (B, C, E ). The high salt (H/S) diet alone did not alter urinary levels (r  0.20).
angiotensinogen levels in sham animals (H/S  Sham; ); however,
Ang II infusions to H/S rats (H/S  Ang II; ) significantly increased
urinary angiotensinogen levels compared with H/S Sham groups using
both methods. Control rats were on a normal salt diet and sham-
operated (N/S  Sham; ). Representative Western blotting analysis
of urinary angiotensinogen was performed at day 7 (C) and post- major urinary protein at pre-treatment (D) and post-treatment (F ).
treatment at day 13 (E). To examine the possibility that enhancement Major urinary protein levels were not altered by either the high salt
of urinary angiotensinogen levels by Ang II infustion is a non-specific diet or and Ang II infusions. *P  0.05 vs. N/S  Sham; †P  0.05 vs.
phenomenon, the membranes were re-probed with an antibody against H/S  Sham.
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that urinary excretion of angiotensinogen was 4.7 nmol/
day in puromycin aminonucleoside-induced nephrotic
rats [18]. In the present study, urinary angiotensinogen
levels based on generation of Ang I upon incubation
with excess renin were in the range of 1 nmol/day (90
pmol/mL). Thus substantial amounts of active angioten-
sinogen appear in the urine and presumably are derived
from angiotensinogen that is secreted into the proximal
tubule fluid [14, 28–30]. It has been shown that angioten-
sinogen concentrations in proximal tubular fluid are
about 300 pmol/mL [14]. These high proximal tubule
angiotensinogen concentrations suggest that much of the
angiotensinogen secretion into the tubules forms Ang I
and may eventually be metabolized or taken up by the
tubular cells. Accordingly, the tubular angiotensinogen
that is ultimately excreted in the urine may provide an
index of intrarenal angiotensinogen production rate. Our
previous studies demonstrating that chronic Ang II infu-
sions in this model led to significant increases in both
angiotensinogen mRNA and protein suggested that the
enhanced intrarenal angiotensinogen levels would be
reflected in the urine. We found that Ang II infusion
increased urinary excretion of angiotensinogen to 4.0
nmol/day, a value similar to that previously reported for
rats with induced renal disease. The increase in urinary
angiotensinogen was not due to urine collection varia-
tions since we demonstrated that urinary excretion rates
of creatinine were similar among the groups at the begin-
ning and end of the protocol, indicating that 24-hour
urine collections reflect 24-hour urine production. In ad-
dition, the equality of urinary creatinine excretion among
groups rules out the possibility that the increase in uri-
nary excretion of angiotensinogen results from the in-
crease in urine volume in the H/S  Ang II group.
Sigmund and colleagues have provided evidence from
studies in transgenic mice overexpressing human renin
and proximal tubule human angiotensinogen supporting
the hypothesis that kidney-specific enhancement of RAS
can participate in the regulation of BP independently of
the systemic RAS [28, 29]. They also demonstrated that
the human angiotensinogen that was only produced in
proximal tubular cells could be recovered in the urine.
Fig. 2. Correlation of Ang II levels and urinary excretion of angioten- In the present study, urine excretion of angiotensino-
sinogen. Urine levels of angiotensinogen after the treatment evaluated gen showed a high correlation with kidney Ang II con-
by radioimmunoassay were plotted against kidney (A) and plasma (B)
tents, but not with plasma Ang II concentrations. TheseAng II levels. Urinary levels of angiotensinogen were highly correlated
with kidney Ang II content, but not with the plasma Ang II level. data demonstrate that urine excretion of angiotensino-
gen most likely reflects intrarenal formation of angio-
tensinogen.
Our previous studies demonstrated that Ang II infu-
DISCUSSION sions resulted in significant increases in renal expression
The presence of angiotensinogen in the urine has been of angiotensinogen protein [13] as well as angiotensino-
known for almost 30 years [15]; however, few reports gen mRNA [11, 12]. We also confirmed that angioten-
have addressed the source of urinary angiotensinogen or sinogen protein is predominantly localized in the proxi-
the normal and pathophysiological roles of urinary an- mal tubules of the rat kidney [12]. The present study
extends these findings by showing that the augmentedgiotensinogen [16–19]. Pedraza-Chaverri et al reported
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angiotensinogen protein, which is presumably secreted reabsorbed by more distal tubular segments. Okamoto
into the tubular lumen, leads to enhanced urinary excre- and colleagues examined intact angiotensinogen and des-
tion of angiotensinogen. Urinary angiotensinogen has a Ang I angiotensinogen in plasma and urine samples of
molecular weight of approximately 52 kD, which is simi- the normal rat and found that the ratio of intact angioten-
lar to the size of the protein in kidney cortex as we sinogen to des-Ang I angiotensinogen was 4:1 in plasma
previously showed [12, 13]. The integrity of the protein and 1:8 in urine [17]. Based on the ratio of urinary intact
identified in the urine is evident by the similarity in angiotensinogen to des-Ang I angiotensinogen of 1:8 [17],
the molecular weights of urinary angiotensinogen and and on the present urine angiotensinogen results from
kidney angiotensinogen. Urine samples did not contain RIA of Ang I formation, we postulate that the total angio-
detectable amounts of the 64 kD isoform that also is tensinogen excretion on the urine was approximately
present in plasma and liver [12, 13]. eight times greater than the values measured, suggesting
It has been suggested that most of the angiotensinogen minimum intrarenal angiotensinogen production rates
formed in proximal tubular cells is destined for secretion of 4 nmol/day during the H/S diet and increasing up to
into the tubular lumen [10, 28, 30]. Lalouel and col- 32 nmol/day in the Ang II-infused rats. Further studies
leagues emphasized the luminal localization of angioten- are needed to provide more quantitative estimates of
sinogen by immunohistochemistry in proximal tubular the changes in intrarenal production rate of the angioten-
cells of the rat kidney, and further showed that the most sinogen in response to long-term Ang II infusions.
of angiotensinogen was detected in the apical compart- In summary, urinary excretion of angiotensinogen was
ment in a polarized monolayer culture of proximal tubu- increased significantly in Ang II-infused rats, which was
lar cells [30]. Thus, it seems likely that urinary angioten- associated with an elevation in kidney Ang II levels.
sinogen excretion may be a useful marker of intrarenal Urine excretion of angiotensinogen was highly corre-
angiotensinogen production. lated with kidney Ang II content, but not with plasma
It is interesting to note that the expression of Ang II Ang II level. These data demonstrate that urinary excre-
type I receptors is more predominant on the luminal tion of angiotensinogen may provide a specific index of
side than on the basolateral side in proximal tubular cells intrarenal activity of the RAS and may provide a useful
[31]. Thus, filtered Ang II from circulating Ang II may method for detecting enhanced intrarenal Ang II activity
link to its receptor on the luminal side of proximal tubu- in the absence of elevated systemic Ang II concentra-
lar cells and luminal activation of the Ang II type I tions. Accordingly, measurements of urinary angioten-
receptor complex may enhance angiotensinogen expres- sinogen levels may be a reliable means of identifying
sion in proximal tubular cells leading to increased angio- Ang II-dependent hypertension.
tensinogen secretion and Ang I formation. These pro-
cesses may be responsible, in part, for the enhanced
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